Moneycontrol PRO
HomeNewsBusinessEconomyCOVID-19 vaccine coverage in India likely to remain under 35% by 2021-end: Report by IMF's Ruchir Agarwal, Gita Gopinath

COVID-19 vaccine coverage in India likely to remain under 35% by 2021-end: Report by IMF's Ruchir Agarwal, Gita Gopinath

On May 21, the Health Ministry said the cumulative number of COVID-19 vaccine doses administered in the country has exceeded 19 crore.

May 22, 2021 / 07:38 IST
IMF Chief Economist Gita Gopinath (Image: AFP)

In a business-as-usual scenario without a significant global vaccination plan, the vaccine coverage in India is expected to remain under 35 percent of the population by the end of 2021, a report penned by International Monetary Fund (IMF) economist Ruchir Agarwal and IMF's Chief Economist Gita Gopinath, has said.

The report proposed a $50 billion plan to end the Covid-19 pandemic, with a target of vaccinating at least 40 percent of the world's population by the end of 2021

On May 21, the Health Ministry said the cumulative number of COVID-19 vaccine doses administered in the country has exceeded 19 crore. The government's CoWin portal showed that this breaks down to 14.4 crore people getting their first dose while 4.14 crore getting their second dose.

The report says that more than 1.1 billion vaccine doses had been administered globally by the end of April 2021. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), which represents pharmaceutical companies around the world, projects an accelerating supply of vaccines. It had stated on April 23 that current projections to produce close to 10 billion doses by the end of 2021 is thought to be feasible.

The authors pointed out that while these estimates remain subject to significant downside risks due to the fragility of the supply chain, the pace of global vaccination reached 20 million doses per day as of the end of April 2021

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

"This is equivalent to 0.25 per 100 people in the world. Even at this pace, under the baseline we should expect conservatively at least 6 billion vaccine doses produced and administered worldwide by the end of 2021. For our business-as-usual projections of vaccine coverage by the end of 2021, we take this conservative estimate of 6 billion doses and treat the industry baseline of 10 billion doses as a potential upside scenario," the report said.

The rate of vaccination in India has swung back and forth, broadly declining over the past two months, mostly owing to a shortage of vaccines. While an average 40 lakh odd doses were administered at the beginning of April, it had dropped to 20 lakh doses, on an average, in the beginning of May. The highest number of doses administered on a single day was 42 lakhs on April 2.

The report mentioned that while India’s health system held up fairly well in the first wave, this time around its health system is so overwhelmed that many are dying because of a lack of medical supplies like oxygen, hospital beds, and medical care. "India is a warning of possible events in other low- and middle-income countries (LMICs) that so far have seemingly escaped the pandemic, including in Africa," it said.

After daily cases remained above the three-lakh mark for 25 straight days in a row, India has seen cases dip below that level for the past three days.

Subhayan Chakraborty
first published: May 21, 2021 08:35 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347